Contact: Matt Schutte, Director of Corporate Communications | 614-675-3686
STERIS Group President joins Omeris Board

Omeris announced today that Charles Immel, senior vice president and group president of STERIS Corporation’s Healthcare division, has joined the organization’s Board of Trustees. Omeris is Ohio’s bioscience membership and development organization.

Mr. Immel is responsible for sales, marketing, manufacturing, development, and support functions for STERIS’s global healthcare business. This group has approximately $800 million in annual revenue and includes capital equipment, consumables, and service provided to hospital sterilization departments, operating theaters, and critical care departments.

A graduate of the Ohio State University, Mr. Immel joined STERIS Corporation in May 2001 as senior vice president, Sales and Marketing, and president, Commercial Operations. Before joining STERIS, he held the position of vice president and general manager of Baxter Healthcare Corporation’s Therapeutic Commercial Business in Europe (1998 to 2001). He also served Baxter Healthcare as vice president and general manager, Plasma Commercial Business; vice president, Global Marketing and Business Development, Recombinant Protein Business; and general manager, Japanese Biotechnology Business.

The Omeris Board of Trustees also includes: John Bantle, II, PhD, Ohio University; Timothy Biro, Ohio Innovation Fund; Thomas Boat, MD, Cincinnati Children’s Hospital Research Foundation; Mark Collar, Procter & Gamble Pharmaceuticals; Mark Coticchia, Case Western Reserve University; Tony Dennis, PhD, Omeris; Mike Hooven, AtriCure; Jane Henney, MD, University of Cincinnati; Peter Kleinhenz, CID Equity Partners; John Rice, PhD, Triathlon Medical Ventures; Richard Rosen, Battelle; Fred Sanfilippo, MD, PhD, The Ohio State University; David Scholl, PhD, Diagnostic Hybrids; Jim Scozzie, PhD, BioEnterprise; and Don Wetherhold, RxPedite.

Omeris is a non-profit organization supported by the Thomas Edison Program of the Ohio Department of Development. Its mission is to accelerate bioscience discovery, innovation and commercialization of global value, driving economic growth, and improving quality of life in Ohio. Omeris is headquartered in Columbus, with regional business development affiliates in Cleveland, Columbus, Cincinnati and Athens.